drugset / Trial / NCT02370238

A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer

NCT02370238 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

The Objectives of this study: The primary objective of the study was to evaluate progression-free survival (PFS) (defined as the number of days between the date of randomization and the date of clinical disease progression (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1, as assessed by Independent Radiology Review, or death for any cause, whichever occured first) in patients with metastatic triple-negative breast cancer (TNBC) treated with the combination of paclitaxel and orally administered reparixin compared to paclitaxel alone. The secondary objectives were: * To determine overall survival (OS). * To evaluate objective response rates (ORR). * To determine median PFS (mPFS). * To assess the safety of the combination of paclitaxel and orally administered reparixin (referred to as combination treatment).

Timeline

Start
2015-07-29
Primary completion
2019-02-20
Completion
2020-03-23

Outcome

Missed primary endpoint

registry p = 0.589; Hazard Ratio (HR) 1.14 (95% CI 0.71 to 1.81); Log Rank NCT02370238 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Reparixin Small molecule 1200 mg —
Background Paclitaxel Small molecule 80 mg/m2 Intravenous

Indications